NMTC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NeuroOne Medical Technologies Corp (NMTC) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available. The company's financials are deteriorating significantly, technical indicators show bearish trends, and there are no strong positive catalysts or trading signals to justify an investment at this time.
The MACD is negative and contracting, RSI is neutral at 53.033, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 4.444, with resistance at 4.993 and support at 3.895. Overall, the technical indicators suggest a bearish trend.
The company has four FDA-cleared products and a distribution partnership with Zimmer Biomet, which could support adoption of its OneRF Ablation System.
Significant financial deterioration in Q1 2026, with revenue down -53.90% YoY, net income down -180.54% YoY, and EPS down -150.00% YoY. Gross margin also dropped significantly by -30.98%. Additionally, there are no recent news updates, no significant insider or hedge fund activity, and no recent congress trading data.
In Q1 2026, the company's revenue dropped to $2,892,635 (-53.90% YoY), net income fell to -$1,437,890 (-180.54% YoY), EPS declined to -0.03 (-150.00% YoY), and gross margin decreased to 54.2 (-30.98% YoY). Overall, the financial performance is highly negative.
JonesResearch analyst Justin Walsh initiated coverage with a Buy rating and a $1.50 price target, citing the company's FDA-cleared products and distribution partnership. However, the price target is significantly below the current price, indicating limited upside potential.
